- Home
- LDWY vs RDHL Comparison
LDWY vs RDHL Comparison
Compare LDWY & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LDWY | RDHL |
|---|---|---|
| Founded | 1990 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2M | 5.6M |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | LDWY | RDHL |
|---|---|---|
| Price | $3.61 | $1.21 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 14.4K | ★ 1.3M |
| Earning Date | 11-10-2025 | 09-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $69,769,000.00 | $9,550,000.00 |
| Revenue This Year | N/A | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.99 | ★ N/A |
| Revenue Growth | 121.91 | ★ 157.62 |
| 52 Week Low | $3.11 | $0.91 |
| 52 Week High | $6.19 | $6.80 |
Technical Indicators
Market Signals| Indicator | LDWY | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 50.22 | 49.94 |
| Support Level | $3.43 | $1.17 |
| Resistance Level | $3.88 | $1.38 |
| Average True Range (ATR) | 0.11 | 0.10 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 44.09 | 59.23 |
Price Performance
Historical ComparisonAbout LDWY Lendway Inc. (DE)
Lendway Inc is a specialty agricultural and finance company focused on making and managing its ag investments in the United States and internationally. The company operates in industries: Specialty Ag, consisting of the Bloomia business.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.